Profile data is unavailable for this security.
About the company
Liaoning Cheng Da Co Ltd is a Chinese company mainly engaged in the pharmaceutical and medical business. The Company operates through four segments. The Biopharmaceutical Segment is mainly engaged in the research and development, production and sales of human vaccines. The Energy Development Segment is mainly engaged in oil shale mining, shale oil production and sales. The Domestic and Foreign Trade Segment is mainly engaged in the export of textiles and apparel and bulk commodity trade. The Company is also engaged in the equity segment. The Company is also engaged in financial investment business divided into long-term investment business and fund business. The Company mainly conducts its business in domestic market.
- Revenue in CNY (TTM)11.29bn
- Net income in CNY346.30m
- Incorporated1993
- Employees3.36k
- LocationLiaoning Cheng Da Co LtdNo. 71 Renmin Road, Zhongshan DistrictDALIAN 116001ChinaCHN
- Phone+86 41 182512731
- Fax+86 41 182691187
- Websitehttps://www.chengda.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Medicine Co., Ltd. | 9.03bn | 977.95m | 15.86bn | 6.23k | 16.12 | 1.53 | -- | 1.76 | 1.02 | 1.02 | 9.54 | 10.75 | 0.694 | 2.94 | 6.01 | 1,450,206.00 | 6.57 | 4.32 | 8.36 | 5.68 | 36.63 | 36.57 | 9.46 | 6.28 | 1.78 | 26.62 | 0.0684 | 58.72 | -3.96 | 2.59 | -20.37 | 3.34 | 12.65 | 0.00 |
| Shanghai Shyndec Pharmaceutical Co Ltd | 11.50bn | 1.08bn | 16.23bn | 11.61k | 14.99 | 1.24 | -- | 1.41 | 0.8071 | 0.8071 | 8.58 | 9.75 | 0.588 | 3.11 | 7.16 | 990,814.20 | 6.99 | 4.85 | 10.16 | 8.17 | 37.73 | 43.00 | 11.88 | 7.03 | 2.03 | -- | 0.1012 | 17.52 | -6.86 | 1.29 | 10.21 | -0.3897 | -2.21 | 0.00 |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 488.45m | -174.40m | 16.36bn | 867.00 | -- | 12.56 | -- | 33.50 | -0.6692 | -0.6692 | 1.86 | 4.92 | 0.1677 | 0.2615 | 4.39 | 563,380.80 | -6.54 | -27.13 | -11.06 | -39.20 | 92.64 | 92.75 | -39.00 | -220.71 | 1.83 | -- | 0.4159 | -- | 27.83 | 211.81 | 39.08 | -- | 41.38 | -- |
| Tonghua Dongbao Pharmaceutical Co Ltd | 2.43bn | 341.31m | 16.77bn | 3.20k | 54.66 | 2.61 | -- | 6.89 | 0.1548 | 0.1548 | 1.25 | 3.24 | 0.3394 | 0.7426 | 3.70 | 760,839.10 | 4.76 | 18.68 | 5.04 | 19.68 | 77.31 | 78.73 | 14.03 | 39.20 | 2.60 | -- | 0.0712 | 41.73 | 10.69 | 2.69 | -26.17 | 6.85 | -14.75 | 4.56 |
| Liaoning Cheng Da Co Ltd | 11.29bn | 346.30m | 17.67bn | 3.36k | 50.93 | 0.598 | -- | 1.56 | 0.2268 | 0.2268 | 7.42 | 19.31 | 0.2371 | 5.28 | 5.77 | 3,365,262.00 | 0.2322 | 3.59 | 0.3297 | 5.21 | 13.90 | 14.15 | 0.9793 | 9.89 | 0.9129 | -- | 0.2831 | 15.93 | -25.97 | -10.97 | -80.95 | -21.26 | 7.04 | -- |
| Shandong Buchang Pharmaceuticals Co Ltd | 11.78bn | -293.31m | 18.54bn | 8.31k | -- | 1.66 | -- | 1.57 | -0.2619 | -0.2619 | 10.76 | 10.09 | 0.5777 | 1.08 | 9.78 | 1,416,955.00 | -2.26 | 3.26 | -3.13 | 4.72 | 58.25 | 74.71 | -3.92 | 4.85 | 0.5070 | 0.1602 | 0.2675 | 121.01 | -11.41 | -0.6219 | 120.85 | -29.93 | -16.56 | -36.72 |
Data as of Nov 01 2024. Currency figures normalised to Liaoning Cheng Da Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 5.68m | 0.37% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 5.49m | 0.36% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 4.72m | 0.31% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.00m | 0.26% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 3.34m | 0.22% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 3.27m | 0.21% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 2.99m | 0.20% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.80m | 0.18% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2024 | 1.40m | 0.09% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 1.10m | 0.07% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
